Kawikova I, Barnes P J, Takahashi T, Tadjkarimi S, Yacoub M H, Belvisi M G
Department of Thoracic Medicine, National Heart and Lung Institute, London, United Kingdom.
Am J Respir Crit Care Med. 1996 Feb;153(2):590-6. doi: 10.1164/ajrccm.153.2.8564103.
8-Epi-prostaglandin F2 alpha (8-epi-PGF2 alpha) is an F2-isoprostane formed via a noncyclooxygenase pathway. We investigated whether 8-epi-PGF2 alpha has any effects on isolated guinea-pig and human airway smooth-muscle tone, and characterized the receptor involved in these effects. Cumulative concentration responses to 8-epi-PGF2 alpha in the absence or presence of prostanoid TP- and EP1-receptors antagonists (ICI 192, 605 and AH 6809, respectively) were compared with the responses to U46619 (a thromboxane A2 mimetic) and PGF2 alpha. 8-epi-PGF2 alpha contracted airway smooth muscle with a rank order of potency of U46619 > PGF alpha > 8-epi-PGF2 alpha for guinea pig and U46619 > 8-epi-PGF2 alpha > PGF2 alpha for human smooth muscle. ICI 192,605 inhibited guinea-pig tracheal contraction produced by U46619 (pA2 = 10.0) with a similar potency to its inhibition of the contraction induced by 8-epi-PGF2 alpha (apparent pKB = 10.2, 10.3), but not that induced by PGF2 alpha (apparent pKB = 6.6). AH 6809 inhibited contraction induced by PGF2 alpha (pA2 = 6.6) with a greater potency than contraction induced by U46619 (apparent pKB = 5.1, 5.2) or 8-epi-PGF2 alpha (apparent pKB = 5.3). In human airways, ICI 192,605 inhibited contraction induced by U46619 and 8-epi-PGF2 alpha with apparent pKB values of 9.5 and 9.4, respectively, and AH 6809 inhibited contraction induced by 8-epi-PGF2 alpha with apparent pKB values of 5.7 and 5.4. We conclude that 8-epi-PGF2 alpha contracts human and guinea-pig airways via prostanoid TP receptors. However, if 8-epi-PGF2 alpha is formed in asthma, its production, unlike that of other prostanoids, would not be inhibited by cyclooxygenase inhibitors.
8-表-前列腺素F2α(8-epi-PGF2α)是一种通过非环氧化酶途径形成的F2-异前列腺素。我们研究了8-epi-PGF2α对分离的豚鼠和人气道平滑肌张力是否有任何影响,并对参与这些作用的受体进行了特性分析。将在不存在或存在前列腺素TP和EP1受体拮抗剂(分别为ICI 192,605和AH 6809)的情况下对8-epi-PGF2α的累积浓度反应与对U46619(一种血栓素A2类似物)和PGF2α的反应进行比较。对于豚鼠气道平滑肌,8-epi-PGF2α使其收缩,效力顺序为U46619 > PGFα > 8-epi-PGF2α;对于人气道平滑肌,效力顺序为U46619 > 8-epi-PGF2α > PGF2α。ICI 192,605抑制U46619引起的豚鼠气管收缩(pA2 = 10.0),其效力与其抑制8-epi-PGF2α诱导的收缩相似(表观pKB = 10.2, 10.3),但对PGF2α诱导的收缩无抑制作用(表观pKB = 6.6)。AH 6809抑制PGF2α诱导的收缩(pA2 = 6.6),其效力大于抑制U46619(表观pKB = 5.1, 5.2)或8-epi-PGF2α(表观pKB = 5.3)诱导的收缩。在人气道中,ICI 192,605抑制U46619和8-epi-PGF2α诱导的收缩,表观pKB值分别为9.5和9.4,AH 6809抑制8-epi-PGF2α诱导的收缩,表观pKB值为5.7和5.4。我们得出结论,8-epi-PGF2α通过前列腺素TP受体使人和豚鼠气道收缩。然而,如果8-epi-PGF2α在哮喘中形成,与其他前列腺素不同,其产生不会被环氧化酶抑制剂抑制。